Malignant pleural mesothelioma co-opts BCL-X L and autophagy to escape apoptosis

April 23, 2021 | Comments Off on Malignant pleural mesothelioma co-opts BCL-X L and autophagy to escape apoptosis

Cell Death & Disease 2021 April 15 [Link] Duo Xu, Shun-Qing Liang, Zhang Yang, Haitang Yang, Rémy Bruggmann, Simone Oberhaensli, Sabina Berezowska, Thomas M Marti, Sean R R Hall, Patrick…

Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis

April 22, 2021 | Comments Off on Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis

Virchows Archiv 2021 April 14 [Link] Nazim Benzerdjeb, Peggy Dartigues, Vahan Kepenekian, Séverine Valmary-Degano, Eliane Mery, Gerlinde Avérous, Anne Chevallier, Marie-Hélène Laverriere, Irène Villa, Olivier Harou, Françoise Galateau Sallé, Laurent…

L1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumors, well-differentiated papillary mesothelial tumors and malignant mesotheliomas

April 21, 2021 | Comments Off on L1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumors, well-differentiated papillary mesothelial tumors and malignant mesotheliomas

Histopathology 2021 April 13 [Link] Georgia Karpathiou, Francois Casteillo, Maroa Dridi, Alexandra Papoudou-Bai, Jean Marc Dumollard, Michel Peoc’h Abstract Malignant mesothelioma (MM), the primary cancer of the mesothelium, is characterized…

Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression

April 20, 2021 | Comments Off on Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression

Clinical and Translational Oncology 2021 April 10 [Link] L Gutierrez-Sainz, P Cruz, S Martinez-Recio, O Higuera, M I Esteban-Rodriguez, F Arias-Lotto, R A Gonzalez, J De Castro-Carpeño Abstract Background: Malignant…

Incidence of mesothelioma and asbestosis by occupation in a diverse workforce

April 19, 2021 | Comments Off on Incidence of mesothelioma and asbestosis by occupation in a diverse workforce

American Journal of Industrial Medicine 2021 April 8 [Link] Nathan L DeBono, Hunter Warden, Chloë Logar-Henderson, Sharara Shakik, Mamadou Dakouo, Jill MacLeod, Paul A Demers Abstract Objective: We sought to…

Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression

April 16, 2021 | Comments Off on Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression

Clinical and Translational Oncology 2021 April 10 [Link] L Gutierrez-Sainz, P Cruz, S Martinez-Recio, O Higuera, M I Esteban-Rodriguez, F Arias-Lotto, R A Gonzalez, J De Castro-Carpeño Abstract Background: Malignant…

P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment

April 15, 2021 | Comments Off on P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment

Frontiers in Oncology 2021 March 22 [Link] Federica Pezzuto, Francesca Lunardi, Luca Vedovelli, Francesco Fortarezza, Loredana Urso, Federica Grosso, Giovanni Luca Ceresoli, Izidor Kern, Gregor Vlacic, Eleonora Faccioli, Marco Schiavon,…

Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma

April 14, 2021 | Comments Off on Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma

Thoracic Cancer 2021 April 8 [Link] Kageaki Watanabe, Yusuke Okuma, Shoko Kawai, Makoto Nagamata, Yukio Hosomi Abstract Background: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered…

NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma

April 13, 2021 | Comments Off on NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma

Cancers 2021 March 29 [Link] Haitang Yang, Sean R R Hall, Beibei Sun, Liang Zhao, Yanyun Gao, Ralph A Schmid, Swee T Tan, Ren-Wang Peng, Feng Yao Abstract (1) Inactivation…

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT

April 12, 2021 | Comments Off on Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT

Cancers 2021 March 4 [Link] Kazuhiro Kitajima, Mitsunari Maruyama, Hiroyuki Yokoyama, Toshiyuki Minami, Takashi Yokoi, Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Kozo Kuribayashi, Takashi Kijima, Seiki Hasegawa, Koichiro Yamakado Abstract…

Categories